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Abstract 
Colorectal cancer (CRC) holds the third highest incidence and cancer related mortality rate 
among men and women in the United States. Unfortunately, there has been little progression 
made in the treatment of this deadly disease once it has spread beyond the colon. It has been 
hypothesize that colon cancer stem cells are implicated in CRC carcinogenesis, metastasis, 
and therapeutic resistance. One of the difficulties in testing these hypotheses is the current 
use of established high-passage cancer cell lines. Long term, high-passage established cell lines 
have cells with stem like properties as they propagate almost indefinitely. These cells are 
thought to be different than the original cancer stem cells in fresh tumors. In order to in-
vestigate cancer stem cells, and molecularly profiling tumors with high fidelity to the original 
primary tumor, one needs to establish suitable primary ultra-low passage cell lines from fresh 
surgical specimens. Here we report the establishment of tumor initiating colon cancer ul-
tra-low passage cell lines by a combination of gentle mechanical, enzymatic dissociation, 
spheroid formation, and followed by two generation xenografts from fresh tumors obtained 
at time of operation. Tumors generated were characterized by morphology, flow cytometry, 
immunofluorescence, and by gene expression. In the future, such a technology can be used to 
produce expeditiously enough material to test for mutations, genetic signatures and molecular 
subtyping readily available for clinical therapeutic decision making. 
Key words: Colon cancer, Fresh Tumor, Cell lines, Spheroids, Cancer Stem Cells. 
Introduction 
Colorectal cancer (CRC) is one of the most ag-
gressive  solid  organ  cancers  and  holds  the  third 
highest incidence and mortality rate amongst the US 
population [1]. Among patients with CRC, approxi-
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mately 50% will eventually develop metastases and 
once metastases ensue prognosis is poor. Recent work 
suggests  the  existence  of  cancer  stem  cells  in  solid 
organ cancers including neoplasms of the colon and 
rectum [2-4]. Literature suggests the existence of can-
cer stem cells in neoplasms of the colon and rectum 
[2-4]. It has been hypothesize that colon cancer stem 
cells are implicated in CRC carcinogenesis, metastasis, 
and  therapeutic  resistance.  Isolation  of  live  cancer 
stem cells has been a limiting step for further investi-
gation of these hypotheses. An in vitro model of CRC 
better reflecting the original tumor must be developed 
through the establishment of ultra-low passage pri-
mary cell lines from clinically available fresh surgical 
specimens.  
Though difficult, the establishment of clinically 
relevant  ultra-low  passage  cell  lines  from  fresh  tu-
mors is potentially more conducive for the study of 
cancer because they are likely to represent more ac-
curately the primary tumor. Cells derived from fresh 
tumors may not directly grow in vitro, from each pa-
tient every time leading to waste of precious samples 
and  data.  Previously,  several  studies  reporting  on 
isolation and culture of fresh human colon epithelial 
tumor cells were critiqued for inefficiency [6-9]. At-
tempts were made to establish cell culture from fresh 
human colon tumors on a short term basis [10]. Im-
portantly, in the future, parallel testing of mutations, 
genetic signatures, chemotherapy and targeted ther-
apy sensitivities will likely be done routinely for every 
patient. Therefore, there is a tremendous need for a 
technology that will generate expeditiously ultra-low 
passage cancer cell lines producing large quantities of 
cells, for multiple clinical testing. The importance of 
generating ultra-low passage cancer cell lines cannot 
be over emphasized. In this study, we report a suc-
cessful  method  for  the  establishment  of  ultra-low 
passage  colon  cancer  primary  cell  lines  from  fresh 
surgical  specimens  using  a  combination  of  gentle 
mechanical,  enzymatic  dissociation,  spheroid  for-
mation, and followed by two generation xenografts 
formation.  
Materials and Methods 
Patients/tissue specimens 
Fresh tumors were obtained from patients with 
radiographic, biochemical, and histologically proven 
CRC who were treated at the Clinical Research Cen-
ter,  National  Cancer  Institute  (NCI),  National  Insti-
tutes of Health (NIH), USA. All patients were enrolled 
on a tissue procurement protocol. Fresh tumors were 
obtained  during  surgical  resection  of  CRC  primary 
and  metastatic  sites  (Table  1).  For  purposes  of  this 
study, we selected one patient with early stage cancer 
and  another  with  advanced  metastatic  cancer.  The 
tissue  procurement  protocol  was  approved  by  the 
NCI Institutional  Review Board prior to enrollment 
and  treatment  of  all  patients  (IRB  Protocol: 
09-C-0079).  
 
 
Table 1. Characteristics of patient’s and tumors used to 
establish ultra-low passage colorectal cancer cell lines. 
  CSCL-01-WE  CSCL-03-BA 
Age at Diagnosis  41  44 
Gender  Female  Female 
Primary Disease Site  Rectum  Colon 
Stage  IV  I 
Primary Pathology  T4N3M1  T1N0M0 
Grade  Moderately Dif-
ferentiated Ade-
nocarcinoma 
Well Differentiat-
ed Adenocarci-
noma 
Classification of specimen 
used for culture 
Fresh Tumor  Fresh Tumor 
 
 
 
Tumor cell isolation and primary culture 
Immediately  following  resection,  tumors  were 
placed  into  40C  normal  saline  with  antibiotics  and 
antifungal, and transported to the laboratory. Once in 
the laboratory, using sterile technique, excess fat and 
normal  tissue  were  removed  and  the  tumors  were 
washed  with  1X  HBSS.  Using  sharp  dissection,  tu-
mors  were  minced  into  1-3  mm3  chunks  and  ap-
proximately 3g of minced tumor was transferred into 
a  gentleMACS  C  tube  (Miltenyi  Biotec,  Germany) 
which contained 5 ml of dissociation medium. Disso-
ciation  medium contained DMEM/F12 (1:1) growth 
medium  (Mediatech,  USA)  supplemented  with  1 
mg/ml  of  collagenase,  type  IV  (Sigma,  USA)  and 
10U/ml of pulmozyme (DNase, Dornase alfa inhala-
tion solution, Genentech, USA). Minced tumors were 
dissociated  gently  by  gentleMACS  dissociator  (Mil-
tenyi Biotec) to yield cell suspensions with a high vi-
ability  rate.  Cell  suspensions  were  created  by  the 
gentleMACS  dissociator  (Miltenyi  Biotec,  Germany) 
through a series of programmable gentle dissociations 
and incubations in humidified atmosphere containing 
5% CO2 at 370C. Cell suspensions were then filtered 
through sterile 70 µm nylon cell strainers (BD Falcon) 
washed with 50 ml 1X HBSS and centrifuged at 1400 
rpm (40C) for 10 min. Cells were re-suspended using 
standard growth medium. Standard growth medium  Journal of Cancer 2012, 3 
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contained DMEM/F12 (1:1) supplemented with 10% 
fetal  bovine  serum  (Gibco,  USA),  10%  glutamine 
(Gibco,  USA),  2%  penicillin/streptomycin  solution 
(Gibco,  USA),  and  1.25  µg/ml  of  Fungizone  (Am-
photencin  B,  Gibco,  USA).  Cell  count  and  viability 
were  determined  by  the  trypan  blue  dye  exclusion 
method using a T4 Cellometer (Nexcelom Bioscience 
LLC, USA).  
Primary organoid cultures 
Cell suspensions were plated into ultra-low at-
tachment tissue culture flask (Type and producer) at a 
concentration of 1x106/ml and cultured in humidified 
atmosphere containing 5% CO2 at 370C. At this stage, 
cells were grown in suspension for 7 days until for-
mation  of  organoid  bodies.  Growing  cells  in  sus-
pended  spheroid-bodies  is  thought  to  increase  the 
relative proportion of stem-like cells, and to rid of the 
fibroblast thus, better potential to result in a stable cell 
line. Suitability for cell propagation and morphology 
were determined in vitro by a phase-contrast micro-
scope (Olympus). Spheroid bodies were passaged by 
fluid  aspiration  and  filtration,  and  used  for  xeno-
grafting  immediately  or  cryopreserved  for  future 
studies, at a concentration of 5x106/ml with freezing 
medium in liquid nitrogen.  
Establishment of ultra-low passage stable hu-
man colorectal cancer cell lines  
Spheroid-bodies  were  harvested  from  primary 
fresh tumor suspension cultures, and injected subcu-
taneously  into  Nude  SCID  mice,  strain: 
Crl:SHO-PrkdcscidHrhr (Charles River, USA). 3x106 cells 
were resuspended in 100 µl of 25% matrigel (BD Bio-
sciences,  USA)  diluted  with  1XHBSS,  and  injected 
subcutaneously into mice. After the tumor grew ap-
proximately to 2 cm2, xenografts were harvested and 
redigested  and  cultured  as  described  above.  Cell 
suspensions  were  placed  into  ultra-low  attachment 
tissue culture flask for spheroid formation at a con-
centration of 1x106/ml with the same growth medium 
and  conditions.  Spheroids  were  harvested  after  6 
days,  resuspended  with  25%  matrigel  as  described 
above  and  were  re-injected  into  the  same  strain  of 
mice. After the tumor grew approximately to 2cm2, 
xenografts were harvested, redigested, and cultured 
as  described  above.  However,  this  time  (passage  3, 
surgery-to-cell line) into normal adherent tissue cul-
ture  flasks  generating  ultra-low  passage  stable  cell 
lines.  Subsequently,  cells  were  grown  for  several 
passages  with  DMEM/F12  (1:1)  growth  medium 
supplemented with 10% FBS (Gibco, USA), 10% glu-
tamine (Gibco, USA), and 1% penicillin streptomycin 
(Gibco, USA) to test for growth stability.  
Histological and morphological evaluation of 
tumors  
At each passage of tumor cells, mouse xenografts 
were fixed in 4% paraformaldehyde and embedded 
into  paraffin  blocks.  Embedded  tissues  were  then 
sliced  into  6  microns  sections.  Sections  were  fixed 
onto glass microscope slides and H&E staining was 
performed.  Cellular  morphology  and  histology  was 
determined  by  a  phase-contrast  microscope  (Olym-
pus) by a board-certified Pathologist. 
Fluorescence confocal microscopy 
To validate the cell of origins, we used fluores-
cence confocal microscopy to test cell cultures estab-
lished  from  mice  xenografts  for  carcinoembryonic 
antigen  (CEA)  expression.  To  retrieve  the  antigen, 
50,000  cells  were  centrifuged  onto  a  charged  glass 
slide  and  fixed  with  4%  paraformaldehyde  for  15 
minutes  at  room  temperature.  Slides  were  subse-
quently immersed in 10 mM Sodium Citrate Buffer, 
pH 6.0 and heated for 3 minutes at 1200C in a pressure 
boiler.  Cells  were  permeabilized  in  PBS  containing 
0.25 % Triton-X-100 for 10 minutes at room tempera-
ture.  To  assess  for  CEA,  goat  polyclonal  pan  CEA 
(D-19) primary antibody (10 µg/ml, Santa Cruz Bio-
technology, USA) and Alexa Fluor® 546 donkey an-
ti-goat  IgG  (H+L)  (1:200  dilution,  Invitrogen,  USA) 
secondary antibody were applied for 1 hour at room 
temperature.  To  assess  CD45  expression,  mouse 
monoclonal anti-human CD45 primary antibody (10 
µg/ml, Invitrogen, USA), and Alexa Fluor® 633 goat 
anti-mouse  IgG  (H+L)  (1:200  dilution,  Invitrogen, 
USA) secondary antibody were applied for 1 hour at 
room  temperature.  Slides  were  mounted  with  Vec-
tashield/DAPI stain (Vector Laboratories H-1200) and 
stored at 4°C in darkness prior to confocal microsco-
py. Confocal images were captured with Zeiss AIM 
software on a Zeiss LSM 510 Confocal System (Carl 
Zeiss Inc.) with a Zeiss Axiovert 100M inverted mi-
croscope and 50 mW argon UV laser tuned to 364 nm 
and a 1 mW HeNe laser tuned to 546 nm, or a 5 mW 
HeNe laser tuned to 633 nm. A 20x objective was used 
at  digital  zoom  settings  of  1  or  2.  Emission  signals 
after  sequential  excitation  of  DAPI  (blue)  and 
Alexa-Fluor 555 (red) or Alexa Fluor 568 (pseudo- red) 
by 364 nm and 543 nm or 633 nm laser lines were ac-
quired with a BP 385-470 filter and LP 560 filter or LP 
650 filter, respectively, using individual photomulti-
pliers.  Bone  marrow  cells  of  NOD/SCID  gamma 
mouse and CD45 positive fraction of human whole 
blood cells were used as controls.   Journal of Cancer 2012, 3 
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Analysis of CEA and CD45 expression using 
flow cytometry  
CEA and CD45 expression was assessed in the 
newly established cell lines by fluorescence-activated 
cell  sorting  (FACS).  In  order  to  analyze  the  cells, 
100,000  cells  were  stained  separately  with 
PE-conjugated  mouse  monoclonal  antibody  (mAb) 
against Human CEA (Abcam, USA; CAT# ab42796) 
and  PE-conjugated  mouse  monoclonal  antibody 
(mAb) against Human CD45 (BD Biosciences, USA; 
CAT#  555483).  Cells  were  incubated  with  the  anti-
bodies for 30 min at 4°C in total darkness. Cells were 
washed  three  times  with  PBS  containing  10  %  FCS 
(Crystalgen, USA; CAT# FCS-50) and analyzed on a 
BDFacsAriaII  flow  cytometer  (BD  Biosciences,  San 
Jose, USA). Bone marrow cells of NOD/SCID gamma 
mouse and CD45 positive fraction of human whole 
blood cells were used as controls. 
Validation of CEA and CD45 by real-time 
quantitative reverse-transcriptase polymerase 
chain reaction (qRT-PCR) 
Total  RNA  was  isolated  from  the  various  cell 
lines  tested  using  a  miRNeasy  Mini  kit  with 
RNase-Free DNase Set (Qiagen, USA) according to the 
manufacturer’s  protocol.  The  concentration  and  the 
purity of the total RNA was determined using ultra-
violet  spectrophotometry  (NanoDrop  Spectropho-
tometer ND-1000, USA). Sample quality was deemed 
acceptable  if  the  OD  260/280  nm  ratio  was  >1.9. 
Samples were stored at -80°C until downstream ap-
plications  were  undertaken.  Reagents  for  real-time 
qRT-PCR,  genomic  DNA  elimination,  re-
verse-transcription, pre-amplification, and primer mix 
were purchased from SABiosciences (Frederick, MD, 
USA).  GAPDH  housekeeping  gene  was  used  as  in-
ternal control. The reverse-transcription cocktail was 
prepared according to the manufacturer’s instruction. 
After  eliminating  genomic  DNA,  equal  volume  of 
reverse-transcription cocktail was added to the RNA 
sample  and  incubated  at  42°C  for  30  minutes.  The 
reaction  was  stopped  by  heating  at  95°C  for  5 
minutes.  Real-Time  qRT-PCR  was  performed  using 
SABioscience RT2 master mix in an ABI 7900 HT sys-
tem  (Applied  Biosystems,  USA)  following  the  sup-
plier’s protocol. The thermal conditions for real-time 
qRT-PCR were set at 95°C for 10 minutes for dena-
turation, followed by 40 cycles of polymerase chain 
reaction with denaturation at 95°C for 15 seconds and 
annealing/extension at 60°C for 2 minutes. Ct values 
were  analyzed  using  the  SABioscience  Company’s 
online software.  
Results 
Establishment of ultra-low passage human 
colorectal cancer cell lines 
Two  colorectal  cancer  cell  lines  (CSCL-01-WE 
and  CSCL-03-BA)  were  established  from  primary 
tumors  of  two  colorectal  cancer  patients  (Table  1). 
Figure 1 summarizes the methodological approaches 
in  details.  Figure  2  shows  a  tumor  formation  (ap-
proximately 2cm2) by CSCL-01-WE cells after only 4 
weeks  of  subcutaneous  injection  of  3  million  cells. 
Combination  of  gentle  mechanical  and  enzymatic 
dissociation of resected tumor provided us adequate 
number of cells for culture with relatively high effi-
ciency 55-60% viability. These cell lines grew both on 
tissue culture treated adherent flaks as a colony and 
formed spheroids in ultra-low attachment flask. Fig-
ure 5 is a representative pictograph of spheroid for-
mation. Figure 3 shows the sequential in vitro growth 
pattern and morphology of the cells before subcuta-
neous  injection  to  animal,  after  1st  xenograft  for-
mation, and final established cell lines. Final cell lines 
were able to recapitulate tumors in nude SCID mice. 
These xenograft tumors matched the histology of the 
patients’ primary tumors by H&E staining (Figure 4).  
Validation of the colorectal cancer origins of 
the ultra-low passage cell lines’  
H&E staining can validate morphologically the 
similarity between the original tumor and the result-
ing xenograft tumors. However, morphological vali-
dation is not sufficient. Immunofluorescence  con-
focal  microscopy  for  CEA  and  CD45  performed  on 
cells passage 6 and later revealed the presence of CEA 
and relative absence of CD45 in both established cell 
lines. We tested CD45 expression to mitigate the ar-
gument that hematopoietic derived cells might pro-
liferate  in  these  conditions  (spheroids)  and  falsely 
resemble  tumors.  The  majority  of  cells  were  CEA 
positive  in  both  the  CSCL-01-WE  and  CSCL-03-BA 
established cell lines (Figure 6). Both of the cell lines 
were  negative  for  CD45  expression  therefore  con-
firming their non-hematopoietic origin (Figure 7). 
In addition, FACS analysis further validated the 
CRC characteristics of the ultra-low passage cell lines. 
The  expression  of  CEA  in  both  cell  lines  (80%  in 
CSCL-01-WE  and  66.5%  in  CSCL-03-BA)  supported 
the microscopic findings, confirming adenocarcinoma 
formation (Figure  8). In both of the established cell 
lines,  less  than  1%  of  the  cells  were  CD45  positive 
(Figure  9),  thus  confirming  the  presence  of  tumor 
cells, and not a proliferation of inflammatory infiltrate 
isolated from the original tumor.   Journal of Cancer 2012, 3 
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Fig. 1 Summary of the methodological approach used for generating readily available ultra-low passage colon cancer cell lines using the 
organoid approach.  Journal of Cancer 2012, 3 
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Fig. 2. A tumor formed by CSCL-01-WE cells after 4 weeks.  
 
 
Fig. 3. Phase-contrast microscopy of the cell lines CSCL-01-WE and CSCL-03-BA (100X, Scale bar: 20µm).  Journal of Cancer 2012, 3 
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Fig. 4 Phase-contrast microscopy of the patients’ primary tumors and xenograft tumors by H&E staining. a H&E staining 
of the CSCL-01-WE patient’s primary rectal tumor showing moderately to poorly differentiated adenocarcinoma. b H&E staining of the 
CSCL-03-BA patient’s primary colon tumor showing moderately differentiated adenocarcinoma. c H&E staining of the first xenograft 
tumor formed by CSCL-01-WE cells showing moderately differentiated adenocarcinoma. d H&E staining of the first xenograft tumor 
formed by CSCL-03-BA cells.  
 
Fig. 5 A representative pictograph of spheroid formation.  Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
203 
 
Fig. 6 CEA expression. To validate CRC origins, here we show CEA expression in cells obtained from final digest. In blue, nuclei stained 
with DAPI; in red, CEA . a and b Micrographs showing presence of CEA in CSCL-01-WE cells and CSCL-03-BA cells respectively. c 
Micrograph showing absence of CEA marker in bone marrow of NOD/SCID gamma mouse (negative control). 
 
 
Fig. 7 Expression of CD45 in ultra-low passage cell lines developed as spheroids. Expression of CD45 was studied by im-
munofluorescence confocal microscopy. In blue, nuclei stained with DAPI; in red, CD45. a, b and c Micrographs showing absence of 
CD45 marker in CSCL-01-WE cells, CSCL-03-BA cells, and in bone marrow of NOD/SCID gamma mouse (negative control) respectively. 
d Micrograph showing presence of CD45 marker in the CD45 positive fraction of human whole blood cells (positive control).   Journal of Cancer 2012, 3 
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Fig. 8 Flow cytometry analysis of CEA expression. a, d Histograms of bone marrow from NOD/SCID gamma mouse stained with 
PE-conjugated mouse monoclonal antibody against Human CEA (negative control). b and e Histograms showing absence of CEA marker 
in  CSCL-01-WE  cells,  CSCL-03-BA  cells  respectively,  when  no  antibody  was  used  (technical  control).  c  and  f  Histograms  of 
CSCL-01-WE cells, CSCL-03-BA cells respectively stained with PE-conjugated mouse monoclonal antibody against Human CEA showing 
presence of CEA in both cell line. 
 
Fig. 9 Flow cytometry analysis of CD45 expression. a Histograms of bone marrow of NOD/SCID gamma mouse stained with 
PE-conjugated mouse monoclonal antibody against Human CD45 (negative control). b Histograms of CD45 positive fraction of human 
whole blood cells without any antibody (technical control). c Histograms of CD45 positive fraction of human whole blood cells stained 
with  PE-conjugated mouse  monoclonal  antibody  against  Human  CD45  (positive  control).  d,  e  Histograms  of  CSCL-01-WE  cells, 
CSCL-03-BA cells respectively stained with PE-conjugated mouse monoclonal antibody against Human CD45 showing absence of CD45 
signal.  Journal of Cancer 2012, 3 
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Fig. 10. a) Real-time qRT-PCR analysis, CEA expression. Here we shows that the two cell lines derived from the original patient’s 
tumors express CEA. b) Real-time qRT-PCR analysis, CD45 expression. Here we shows that the two cell lines derived from 
patient tumors express extremely low levels of the hematopoietic cell marker CD45. 
 
 
Finally, gene expression analysis using qRT-PCR 
further validated the CRC origins of the tumors gen-
erated  by  the  dual  approach:  Organoid-Xenografts. 
These results revealed that CEA was highly expressed 
in both established cell lines, 69.27 +- 31.39 (p=0.010) 
folds  in  CSCL-01-WE  and  85.50  +-  37.04  (p=0.012) 
folds in CSCL-03-BA compared to (negative control) 
mouse bone marrow cells (Figure 10a There was no 
significant CD45 expression in these cell lines (Figure 
10b). 
Discussion 
The establishment of ultra-low passage CRC cell 
lines readily available for clinical testing and cancer 
stem  cells  investigations  is  technically  challenging. 
Time invested in establishing CRC cell lines directly 
from  patient  samples  pays  dividends  as  these  lines 
serve  as  an  optimal  in vitro  model  for  downstream 
testing. Here we show that using a method thought to 
be conducive for stem cells proliferation results in a 
reliable method to produce ultra-low passage tumor 
initiating  cell  lines  that  can  provide  expeditiously 
enough cells for further investigations.  
Because  of  the  importance  of  the  cancer  stem 
cells hypothesis suggesting a role in tumor initiating, 
metastasis  and  therapeutic  failure  for  cancer  stem 
cells, [2-4], we hypothesize that generating ultra-low 
passage cell lines will result in a more accurate depic-
tion  of  the  original  tumor.  Although  intuitive  this 
hypothesis  demands  further  study  and  beyond  the 
scope of this paper. Thus the purpose of the current 
study was to establish ultra-low passage human col-
orectal cancer cell lines directly from surgical speci-
mens.  
In this report, we present our optimized protocol 
using a spheroid enhanced culture with two genera-
tion xenografts. This was preferred for two reasons. 
First,  the  spheroid  formation  in  this  approach  per-
mitted us to eliminate fibroblasts and other non tumor 
cells  from  the  culture.  Second,  literature  suggests 
spheroid formation maintains stem-like characteristic 
of  the  cancer  cells  [11].  We  previously  reported  a 
novel  methodology  to  isolate  unique  population  of 
cancer  stem  cells  i.e.  label  retaining  cancer  cells 
(LRCC) [5]. To test whether LRCC isolated for these 
cell lines express cancer-stem cells markers, we iso-
lated  LRCC  as  putative  cancer  stem  cells  and  non- 
label-retaining cancer cells (non-LRCC) as described 
previously  [5].  Real-time  qRT-PCR  analysis  showed 
that  LRCC  express  significantly  higher  levels  of  al- Journal of Cancer 2012, 3 
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dehyde dehydrogenase 1 family member A1, a colo-
rectal cancer stem cells marker (ALDH1A1, 2.6 +/- 0.3 
folds, p=0.0005) and delta-like 1 (DLL1, 139.6 +/- 23.8 
folds,  p=0.0054)  compared  to  non-LRCC  (Supple-
mentary Figure 1). Other investigators reported that 
ALDH1A1 is a cancer stem cell marker [12] and DLL1 
is an important factor in the Notch signaling pathway 
that is required to maintain colon stem cells pheno-
type [12, 13]. High levels of ALDH1A1 and DLL1 gene 
expressions in LRCC suggest that the established cell 
lines would serve as a good tool for cancer stem cell 
research.  
In summary, we have demonstrated a conven-
ient  method for the establishment  of ultra-low pas-
sage primary human CRC cell lines from fresh surgi-
cal specimens. This protocol could be used to establish 
cell lines from fresh surgical specimens for other his-
tologies.  Generation  of  large  quantities  of  purified 
ultra-low passage cancer cells will be imperative in 
the  future  for  “real-time”  molecular  and  sensitivity 
testing  expeditiously  available  for  clinical  decision 
making. The protocol presented in this report is im-
portant as it offers an optimal in vitro model for a bone 
fide method for the production of ultra-low passage 
cell lines from fresh surgical specimens. 
Supplementary Material 
Supplementary Figure 1.  
http://www.jcancer.org/v03p0196s1.pdf 
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